Zimmer Biomet’s (ZBH) “Buy” Rating Reiterated at BTIG Research

BTIG Research restated their buy rating on shares of Zimmer Biomet (NYSE:ZBH) in a research report report published on Tuesday morning,Benzinga reports. The firm currently has a $112.00 price objective on the medical equipment provider’s stock.

Other analysts also recently issued reports about the stock. Evercore raised shares of Zimmer Biomet from an “in-line” rating to an “outperform” rating and lifted their price objective for the stock from $94.00 to $120.00 in a report on Monday, January 5th. JPMorgan Chase & Co. restated a “neutral” rating and set a $100.00 price target (down previously from $115.00) on shares of Zimmer Biomet in a research report on Thursday, November 6th. Stifel Nicolaus set a $110.00 price target on Zimmer Biomet in a research note on Wednesday, November 5th. Wall Street Zen upgraded Zimmer Biomet from a “hold” rating to a “buy” rating in a research report on Saturday, January 17th. Finally, The Goldman Sachs Group cut Zimmer Biomet from a “neutral” rating to a “sell” rating and set a $93.00 price objective on the stock. in a report on Friday, January 9th. One investment analyst has rated the stock with a Strong Buy rating, eight have assigned a Buy rating, nine have assigned a Hold rating and three have given a Sell rating to the company. According to data from MarketBeat.com, Zimmer Biomet presently has an average rating of “Hold” and an average price target of $106.20.

Zimmer Biomet Stock Down 0.5%

Shares of NYSE ZBH opened at $95.14 on Tuesday. The company has a current ratio of 1.98, a quick ratio of 1.39 and a debt-to-equity ratio of 0.55. The business has a 50-day moving average of $90.05 and a 200-day moving average of $95.64. The firm has a market capitalization of $18.85 billion, a price-to-earnings ratio of 26.87, a PEG ratio of 2.71 and a beta of 0.62. Zimmer Biomet has a 12 month low of $84.59 and a 12 month high of $114.44.

Zimmer Biomet (NYSE:ZBH) last announced its earnings results on Tuesday, February 10th. The medical equipment provider reported $2.42 earnings per share for the quarter, beating analysts’ consensus estimates of $2.38 by $0.04. Zimmer Biomet had a net margin of 8.56% and a return on equity of 12.93%. The business had revenue of $2.24 billion for the quarter, compared to the consensus estimate of $2.22 billion. During the same period last year, the firm posted $2.31 earnings per share. Zimmer Biomet’s quarterly revenue was up 10.9% on a year-over-year basis. Zimmer Biomet has set its FY 2026 guidance at 8.300-8.450 EPS. Sell-side analysts expect that Zimmer Biomet will post 8.22 earnings per share for the current fiscal year.

Zimmer Biomet Dividend Announcement

The business also recently announced a quarterly dividend, which was paid on Friday, January 30th. Stockholders of record on Tuesday, December 30th were paid a $0.24 dividend. This represents a $0.96 dividend on an annualized basis and a dividend yield of 1.0%. The ex-dividend date of this dividend was Tuesday, December 30th. Zimmer Biomet’s payout ratio is 27.12%.

Hedge Funds Weigh In On Zimmer Biomet

Several institutional investors and hedge funds have recently bought and sold shares of ZBH. Vanguard Group Inc. lifted its position in Zimmer Biomet by 0.8% in the fourth quarter. Vanguard Group Inc. now owns 23,483,741 shares of the medical equipment provider’s stock valued at $2,111,658,000 after purchasing an additional 192,517 shares during the last quarter. Dodge & Cox increased its stake in shares of Zimmer Biomet by 5.1% in the third quarter. Dodge & Cox now owns 23,216,173 shares of the medical equipment provider’s stock worth $2,286,793,000 after buying an additional 1,118,710 shares during the period. Capital International Investors increased its stake in shares of Zimmer Biomet by 11.5% in the third quarter. Capital International Investors now owns 7,550,754 shares of the medical equipment provider’s stock worth $743,749,000 after buying an additional 778,467 shares during the period. Franklin Resources Inc. raised its holdings in Zimmer Biomet by 43.2% during the 4th quarter. Franklin Resources Inc. now owns 6,685,987 shares of the medical equipment provider’s stock valued at $601,204,000 after buying an additional 2,017,857 shares during the last quarter. Finally, American Century Companies Inc. boosted its position in Zimmer Biomet by 8.7% during the 2nd quarter. American Century Companies Inc. now owns 5,709,370 shares of the medical equipment provider’s stock valued at $520,752,000 after buying an additional 458,903 shares during the period. 88.89% of the stock is currently owned by institutional investors.

Zimmer Biomet News Summary

Here are the key news stories impacting Zimmer Biomet this week:

• Positive Sentiment: Q4 beat and buyback — ZBH topped estimates on revenue and EPS, and the company announced a new buyback that pushed the stock higher after results. Positive near-term cash-return and sales momentum were highlighted. Article Title
• Positive Sentiment: Buy-side upgrade — BTIG Research issued a “Buy” on ZBH, supporting upside sentiment among some investors. Article Title
• Positive Sentiment: Index inclusion/lift — Coverage noted ZBH’s results helped lift the Russell 1000 Healthcare index, signaling industry-level recognition of the quarter. Article Title
• Neutral Sentiment: Analyst price-target moves — Citigroup and Wells Fargo raised ZBH price targets to $98 while keeping neutral/equal-weight ratings, which signals modest upside but not a broad bullish repositioning. Article Title
• Neutral Sentiment: Hold reaffirmation — Needham reaffirmed a “Hold” on ZBH, reflecting mixed analyst conviction despite the beat. Article Title
• Neutral Sentiment: Sector context — A MarketBeat piece comparing healthcare earnings highlights peers (e.g., AstraZeneca) outperforming in profit growth, which provides cross-checks for relative performance but is not company-specific. Article Title
• Negative Sentiment: Guidance caution from salesforce changes — Deep-dive coverage flagged a U.S. salesforce overhaul that prompted management to strike a measured tone on FY26 guidance, introducing execution risk that likely weighs on the stock today. Article Title
• Negative Sentiment: Measured tone on guidance in the earnings call — Transcripts and coverage emphasize that while Q4 beat, management set cautious FY26 commentary and guidance range, which may limit investor upside until execution is clearer. Article Title

About Zimmer Biomet

Zimmer Biomet (NYSE: ZBH) is a global medical device company focused on musculoskeletal healthcare. Headquartered in Warsaw, Indiana, the company designs, manufactures and markets a broad portfolio of products used to treat joint disorders, bone disorders and related conditions. Its customer base includes orthopaedic and dental surgeons, hospitals, ambulatory surgery centers and other healthcare providers that rely on implants, instruments and related services for reconstructive and restorative procedures.

The company’s product offerings span joint replacement systems for hips, knees and shoulders; trauma and extremities implants; spine and thoracic solutions; dental and craniomaxillofacial implants and prosthetics; and sports medicine devices.